-5%
Deflazacort exerts its effect by inhibiting phospholipase A2, reducing prostaglandin production and other inflammatory mediators. It also suppresses immune system activity by decreasing cytokine and inflammatory chemical release, producing both anti-inflammatory and immunosuppressive effects.
Cordef (Deflazacort) is used in the management of:
- Severe allergic reactions including anaphylaxis and bronchial asthma
- Autoimmune disorders such as rheumatoid arthritis, juvenile chronic arthritis, SLE, dermatomyositis, and mixed connective tissue disease (excluding systemic sclerosis)
- Vasculitic and granulomatous diseases like polyarteritis nodosa and sarcoidosis
- Bullous and inflammatory skin diseases such as pemphigus, bullous pemphigoid, and pyoderma gangrenosum
- Renal and inflammatory conditions, including minimal change nephrotic syndrome and acute interstitial nephritis
- Rheumatic carditis
- Inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease
- Ocular inflammatory disorders like uveitis and optic neuritis
- Hematological and malignant conditions, including autoimmune hemolytic anemia, ITP, acute and lymphoid leukemia, lymphoma, and multiple myeloma
- Immunosuppression in organ transplantation